AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Choline-phosphate cytidylyltransferase B

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9Y5K3

UPID:

PCY1B_HUMAN

Alternative names:

CCT-beta; CTP:phosphocholine cytidylyltransferase B; Phosphorylcholine transferase B

Alternative UPACC:

Q9Y5K3; A8IX00; B2RCX8; B4DK10; E9PD84; O60621; Q86XC9

Background:

Choline-phosphate cytidylyltransferase B, known by alternative names such as CCT-beta and Phosphorylcholine transferase B, plays a pivotal role in phosphatidylcholine biosynthesis through the CDP-choline pathway. This enzyme catalyzes a crucial rate-limiting step, underscoring its importance in cellular membrane formation and maintenance.

Therapeutic significance:

Understanding the role of Choline-phosphate cytidylyltransferase B could open doors to potential therapeutic strategies. Its central function in phospholipid metabolism suggests its potential impact on disorders related to membrane dynamics and lipid imbalances.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.